3,3-ethylenedioxy-5α,17β-dihydroxy-17-(3,3,3-trifluoro-1-propynyl)-11β-{4'-[1',1'-(ethylenedioxy)-ethyl]phenyl}-estr-9-ene | 1421036-59-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3,3-ethylenedioxy-5α,17β-dihydroxy-17-(3,3,3-trifluoro-1-propynyl)-11β-{4'-[1',1'-(ethylenedioxy)-ethyl]phenyl}-estr-9-ene
• 英文别名: 3,3-ethylenedioxy-5a,17β-dihydroxy-17-(3,3,3-trifluoro-1-propynyl)-11β-{4'-[1',1'-(ethylenedioxy)-ethyl]phenyl}-estr-9-ene；3,3-ethylenedioxy-5α,17β-dihydroxy-17-(3,3,3-trifluoro-1-propynyl)-11'-{4'-[1',1'-(ethylenedioxy)-ethyl]phenyl}-estr-9-ene；(5'R,8'S,11'R,13'S,14'S,17'S)-13'-methyl-11'-[4-(2-methyl-1,3-dioxolan-2-yl)phenyl]-17'-(3,3,3-trifluoroprop-1-ynyl)spiro[1,3-dioxolane-2,3'-2,4,6,7,8,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-5',17'-diol
• CAS: 1421036-59-0
• 化学式: C₃₃H₃₉F₃O₆
• 分子量: 588.664
• InChiKey: BZVZQSRTTOEJPG-NWSBRXQPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  42
• 可旋转键数：
  3
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  77.4
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  3,3-ethylenedioxy-5α,17β-dihydroxy-17-(3,3,3-trifluoro-1-propynyl)-11β-{4'-[1',1'-(ethylenedioxy)-ethyl]phenyl}-estr-9-ene 在 硫酸 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 以87%的产率得到11β-(4'-acetylphenyl)-17β-hydroxy-17-(3,3,3-trifluoro-1-propynyl)-estra-4,9-diene-3-one
  参考文献：
  名称：

  [EN] PROGESTERONE ANTAGONISTS
  [FR] ANTAGONISTES DE PROGESTÉRONE

  摘要：

  本文描述了一些化合物，它们要么作为纯抗孕激素，要么作为具有部分激动活性的抗孕激素，并且使用这些化合物治疗癌症的方法。

  公开号：

  WO2013016725A1
• 作为产物：
  描述：

  2-溴-3,3,3-三氟丙烯 、 3,3-ethylenedioxy-5α-hydroxy-11β-{4'-[1',1'-(ethylenedioxy)-ethyl]phenyl}-estr-9-ene-17-one 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.83h， 以70%的产率得到3,3-ethylenedioxy-5α,17β-dihydroxy-17-(3,3,3-trifluoro-1-propynyl)-11β-{4'-[1',1'-(ethylenedioxy)-ethyl]phenyl}-estr-9-ene
  参考文献：
  名称：

  [EN] PROGESTERONE ANTAGONISTS
  [FR] ANTAGONISTES DE PROGESTÉRONE

  摘要：

  本文描述了一些化合物，它们要么作为纯抗孕激素，要么作为具有部分激动活性的抗孕激素，并且使用这些化合物治疗癌症的方法。

  公开号：

  WO2013016725A1

文献信息

• PROGESTERONE ANTAGONISTS
  申请人：Nickisch Klaus

  公开号：US20130029953A1

  公开（公告）日：2013-01-31

  Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.

  本文描述了一些化合物，它们可以作为纯抗孕激素或具有部分激动活性的抗孕激素，并且使用这些化合物的方法治疗癌症。
• Synthesis and biological evaluation of partially fluorinated antiprogestins and mesoprogestins
  作者：Klaus Nickisch、Walter Elger、James Cessac、Narkunan Kesavaram、Baishakhi Das、Robert Garfield、Shao-Qing Shi、Olga Amelkina、Reinhard Meister

  DOI：10.1016/j.steroids.2012.09.010

  日期：2013.2

  A series of antiprogestins have been synthesized by partially fluorinating the steroid molecule in positions relevant for receptor binding. By introducing fluorine at the exo-methylene of the 17 spirofuran ring, we obtained partial agonists (mesoprogestins) with significant applications for antiproliferative and antiovulatory treatment strategies in gynecological therapy such as uterine fibroids, endometriosis and heavy menstrual bleeding. Compared to the standard drug RU486, our synthesized compounds exhibited considerable dissociation between antiprogestational and antiglucocorticoid PR receptors. Furthermore, our studies have shown that pure antiprogestins can be generated by partially fluorinating the 17 propenyl and propynl group or by substituting the 4' acetyl phenyl group in the 11 position using trifluromethyl group. (C) 2012 Elsevier Inc. All rights reserved.
• Synthesis and antiprogestational properties of novel 17-fluorinated steroids
  作者：Klaus Nickisch、Hareesh B. Nair、Narkunan Kesavaram、Baishakhi Das、Robert Garfield、Shao-Qing Shi、Shylesh S. Bhaskaran、Sandra L. Grimm、Dean P. Edwards

  DOI：10.1016/j.steroids.2013.04.003

  日期：2013.9

  Progesterone receptor (PR) plays a key role in reproductive functions, and compounds that inhibit progesterone action (antiprogestins) have potential use in the treatment of estrogen- and progesterone-dependent diseases, including uterine leiomyomas and breast cancer. In the present study, we chemically synthesized novel 17-fluorinated steroids and evaluated the cytotoxicity profiles of these compounds in T47D breast cancer cells compared to the activity of known antiprogestins, including ZK230 211, RU-486, CDB2914, CDB4124 and ORG33628. We analyzed in vitro receptor-binding assays and PR-transactivation assays to establish the antiprogestational activity of these molecules. The representative anti-progestin EC304 was found to inhibit in vitro tumorigenicity in a dose-dependent fashion in T47D cells by a colony formation assay at 1 and 10 nM concentrations. The potent in vivo antiprogestational activity of EC304 was also demonstrated in an antinidation assay for the interruption of early pregnancy in rats. The strong antiprogestational activity and absence of antiglucocorticoid activity in EC compounds may demonstrate their utility in the treatment of leiomyoma, endometriosis and breast cancer. (C) 2013 Elsevier Inc. All rights reserved.